Company Filing History:
Years Active: 2006-2016
Title: Katalin Bíró: Innovator in Pharmaceutical Composition and Molecular Chaperone Enhancement
Introduction
Katalin Bíró is a notable inventor based in Budapest, Hungary. She has made significant contributions to the field of pharmaceuticals, particularly in antiviral compositions and methods for enhancing cellular production of molecular chaperones. With a total of 3 patents, her work has the potential to impact various therapeutic areas.
Latest Patents
One of her latest patents is an antiviral and immune stimulant pharmaceutical composition. This invention relates to a novel formulation containing 20-85 mass % of a ω-3-polyunsaturated fatty acid ester, derived from fish oil concentrate. The composition also includes 1-lysine or a salt thereof, and optionally a zinc salt, selenium, or a selenium compound, along with various additives and carrier ingredients.
Another significant patent involves a method of enhancing the cellular production of molecular chaperones. This method increases the expression of a molecular chaperone in cells exposed to physiological stress. It involves treating the cells with an effective amount of a specific hydroxylamine derivative to increase stress or administering the derivative before exposure to stress. The invention also includes novel hydroxylamine derivatives and pharmaceutical or cosmetic compositions containing these compounds.
Career Highlights
Katalin has worked with several companies throughout her career, including Cytrx Corporation and Sinnex Muszaki Fejleszto Es Tanacsado Kft. Her experience in these organizations has contributed to her expertise in pharmaceutical innovations.
Collaborations
She has collaborated with notable colleagues such as Andrea Jednákovits and László Vígh. These partnerships have likely enriched her research and development efforts.
Conclusion
Katalin Bíró's innovative work in antiviral compositions and molecular chaperone enhancement showcases her significant contributions to the pharmaceutical field. Her patents reflect a commitment to advancing medical science and improving therapeutic options.